SCHEDULE 13G/A: Suvretta Capital Management and Affiliates Disclose Significant Passive Stake in Kura Oncology, Inc.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, revealing a combined passive beneficial ownership of 9.4% in Kura Oncology, Inc.'s common stock.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen collectively reported beneficial ownership of 7,561,000 shares of Kura Oncology, Inc. common stock as of March 31, 2025.
• This aggregate ownership represents 9.4% of Kura Oncology, Inc.'s outstanding common stock.
• Averill Master Fund, Ltd., an advisory client of Suvretta Capital Management, LLC, directly holds 6,922,080 shares, representing 8.6% of the class.
• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC, and his beneficial ownership mirrors that of Suvretta.
• The filing indicates shared voting and shared dispositive power over the reported shares for all reporting persons.
• The reported shares include those that may be acquired upon the exercise of pre-funded warrants with an exercise price of $0.0001 per share and no expiration date.
• The exercise of these pre-funded warrants is subject to a beneficial ownership limitation, typically 9.99%, which can be increased to 19.99% with 61 days' notice to the Issuer.
• The filing is an Amendment No. 5, updating previous ownership disclosures.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Kura Oncology, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook. The sentiment is neutral.

Positives

• The disclosure of a significant passive stake by institutional investors like Suvretta Capital Management and its affiliates may signal confidence in Kura Oncology, Inc.'s long-term prospects.
• Increased institutional ownership can enhance a company's visibility and potentially attract further investment.

Risks

• The pre-funded warrants are not all presently exercisable due to beneficial ownership limitations (Maximum Percentage of 9.99%, extendable to 19.99% after 61 days' notice), which could affect the timing and extent of their conversion into common stock.
• The number of shares that may be issued upon exercise of the pre-funded warrants can change based on fluctuations in Kura Oncology's outstanding common stock.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Kura Oncology, Inc.'s business operations, financial performance, or strategic direction. It solely focuses on the beneficial ownership stake of the reporting entities.

Industry Context

This filing is a standard disclosure of significant passive ownership by institutional investors in a publicly traded company. While it doesn't directly reflect broader industry trends, the presence of substantial institutional investment is common in the biotechnology and pharmaceutical sectors, where companies like Kura Oncology operate.

Related Party Transactions

• Suvretta Capital Management, LLC acts as an investment adviser to Averill Master Fund, Ltd., and Aaron Cowen is the control person for Suvretta Capital Management, LLC. All reported securities are directly owned by advisory clients of Suvretta Capital Management, LLC.

Stakeholder Impact

• Shareholders may view the significant institutional ownership as a positive signal, potentially increasing investor confidence and market liquidity.
• The passive nature of the stake indicates no immediate intent to influence corporate control, which may provide stability for existing management and strategic direction.

Key Dates

Keywords

Kura Oncology, Schedule 13G, beneficial ownership, institutional investment, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, common stock, pre-funded warrants, passive stake, SEC filing